Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. DOI Creative Commons
Sai‐Hong Ignatius Ou, Xiuning Le, Misako Nagasaka

и другие.

Lung Cancer Targets and Therapy, Год журнала: 2024, Номер Volume 15, С. 87 - 114

Опубликована: Июнь 1, 2024

Abstract: The year 2024 is the 20 th anniversary of discovery activating epidermal growth factor receptor ( EGFR ) mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been made treatment NSCLC based on this discovery. Some these studies led to seismic changes concept oncology research and spurred beyond NSCLC, leading a current true era precision for all solid tumors. We now routinely molecularly profile tumor types even plasma samples patients with multiple actionable driver mutations, independent patient clinical characteristics nor profiling limited advanced incurable stage. are increasingly monitoring responses detecting resistance targeted therapy by using genotyping. Furthermore, we early-stage appropriate adjuvant an eventual potential "cure" EGFR+ which societal implication implementing screening never-smokers as most never-smokers. All were unfathomable 2004 when five papers that described "discoveries" (del19, L858R, exon insertions, "uncommon" mutations) published. To commemorate anniversary, assembled global panel thoracic medical experts select top (publications or congress presentation) from years since seminal December 31, 2023 cutoff date inclusion be voted on. Papers ranked 21 30 considered "honorable mention" also annotated. Our objective their annotations about impact will serve "syllabus" education future trainees. Finally, mentioned practice-changing trials reported. One them, LAURA was published online June 2, not included list but surely highly if consensus survery performed again 25 anniversay (i.e. mutations). Keywords: expert panel, papers, 20th

Язык: Английский

Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study DOI
Gee‐Chen Chang, Chao‐Hua Chiu, Chong‐Jen Yu

и другие.

The Lancet Respiratory Medicine, Год журнала: 2023, Номер 12(2), С. 141 - 152

Опубликована: Ноя. 29, 2023

Язык: Английский

Процитировано

60
Artificial Intelligence in Lung Cancer Screening: The Future Is Now DOI Open Access
Michaela Cellina, Laura Maria Cacioppa, Maurizio Cè

и другие.

Cancers, Год журнала: 2023, Номер 15(17), С. 4344 - 4344

Опубликована: Авг. 30, 2023

Lung cancer has one of the worst morbidity and fatality rates any malignant tumour. Most lung cancers are discovered in middle late stages disease, when treatment choices limited, patients’ survival rate is low. The aim screening identification malignancies early stage more options for effective treatments available, to improve outcomes. desire efficacy efficiency clinical care continues drive multiple innovations into practice better patient management, this context, artificial intelligence (AI) plays a key role. AI may have role each process workflow. First, acquisition low-dose computed tomography programs, AI-based reconstruction allows further dose reduction, while still maintaining an optimal image quality. can help personalization programs through risk stratification based on collection analysis huge amount imaging data. A computer-aided detection (CAD) system provides automatic potential nodules with high sensitivity, working as concurrent or second reader reducing time needed interpretation. Once nodule been detected, it should be characterized benign malignant. Two approaches available perform task: first represented by segmentation consequent assessment lesion size, volume, densitometric features; consists first, followed radiomic features extraction characterize whole abnormalities providing so-called “virtual biopsy”. This narrative review aims provide overview all possible applications screening.

Язык: Английский

Процитировано

56
Non-small-cell lung cancer DOI
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn

и другие.

Nature Reviews Disease Primers, Год журнала: 2024, Номер 10(1)

Опубликована: Сен. 26, 2024

Язык: Английский

Процитировано

37
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer DOI Creative Commons
Christopher H. Grant, Misako Nagasaka

Cancer Treatment Reviews, Год журнала: 2024, Номер 126, С. 102724 - 102724

Опубликована: Март 27, 2024

Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy chemotherapy. A majority of these studies excluded patients EGFR ALK alterations. There several completed ongoing trials evaluating neoadjuvant treatment EGFR-TKI monotherapy, therapy chemotherapy, immunotherapy. Here, we review clinical discuss current trials' potential benefits, challenges, future directions in the field.

Язык: Английский

Процитировано

12
Artificial intelligence-based plasma exosome label-free SERS profiling strategy for early lung cancer detection DOI
Dechan Lu,

Zhikun Shangguan,

Zhehao Su

и другие.

Analytical and Bioanalytical Chemistry, Год журнала: 2024, Номер 416(23), С. 5089 - 5096

Опубликована: Июль 17, 2024

Язык: Английский

Процитировано

9
Gender Disparities and Lung Cancer Screening Outcomes Among Individuals Who Have Never Smoked DOI Creative Commons
Yeon Wook Kim, Dong-Hyun Joo, So Yeon Kim

и другие.

JAMA Network Open, Год журнала: 2025, Номер 8(1), С. e2454057 - e2454057

Опубликована: Янв. 15, 2025

Importance Lung cancer in individuals who have never smoked (INS) is a growing global concern, with rapidly increasing incidence and proportion among all lung cases. Particularly East Asia, opportunistic screening (LCS) programs targeting INS gained popularity. However, the sex-specific outcomes drawbacks of remain unexplored, data predominantly focused on women. Objective To compare LCS between Asian women men no smoking history. Design, Setting, Participants This multicenter cohort study was conducted at health checkup centers South Korea from 2009 to 2021. included aged 50 80 years history underwent low-dose computed tomography (LDCT) screening. Data were retrospectively analyzed November 2023 June 2024. Exposures Opportunistic LDCT for cancer. Main Outcomes Measures followed up until December 2022 outcome death. diagnosis, diagnostic characteristics, clinical course, cancer–specific deaths (LCSD) compared men. Results A total 21 062 participants (16 133 [76.6%] 4929 [23.4%] men) mean (SD) age 59.8 (7.2) included. From baseline screening, 176 (139 [0.9%] 37 [0.8%]) diagnosed (screen-detected); 131 139 (94.3%) 33 (89.2%) stage 0 I disease, (95.7%) 36 (97.3%) having adenocarcinoma. There significant sex-based differences or histologic type distribution. Among screened individuals, LCSD reported 8 3 during follow-up 83.8 (41.7) months. Multivariable analyses found association sex cumulative hazards diagnosis (adjusted hazard ratio [aHR], 0.90 [95% CI, 0.64-1.26] vs women) (aHR, 1.06 0.28-4.00] women). The estimated 5-year survival rate 97.7% 100% screen-detected cancer, showing differences. Conclusions Relevance In this detected distribution, LCSD. These findings suggest that would experience similar risks overdiagnosis little benefit when exposed indiscriminate

Язык: Английский

Процитировано

1
Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not DOI
Gerard A. Silvestri, Robert P. Young, Nichole T. Tanner

и другие.

Journal of Thoracic Oncology, Год журнала: 2024, Номер 19(8), С. 1155 - 1163

Опубликована: Авг. 1, 2024

Язык: Английский

Процитировано

6
Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers DOI Creative Commons
Julie Wu, Heather A. Wakelee, Summer S. Han

и другие.

Journal of Clinical Oncology, Год журнала: 2023, Номер 41(27), С. 4341 - 4347

Опубликована: Авг. 4, 2023

Lung cancer screening has been demonstrated to reduce lung mortality, but its benefits must be weighed against the potential harms of unnecessary procedures, false-positive radiological findings, and overdiagnosis. Individuals at highest risk are more likely maximize while minimizing harm from screening. Although current guidelines recommended by US Preventive Services Task Force (USPSTF) only consider age smoking history for eligibility, National Comprehensive Cancer Network other society recommend on basis individualized assessment including family history, environmental exposures, presence chronic disease. Risk prediction models have developed integrate various factors into an score. Previous evidence showed that model-based eligibility could improve sensitivity detecting cases without reducing specificity. Furthermore, recent advances in biomarkers enhanced performance identifying relative USPSTF criteria. These can used guide shared decision-making discussions before proceeding with This study aims provide a concise overview these emerging role biomarker testing facilitate conversations patients. The goal was assist clinicians assessing individual patient risk, leading informed decision making.

Язык: Английский

Процитировано

14
Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer DOI Creative Commons

Chi-Liang Wang,

Kuo-Hsuan Hsu,

Ya‐Hsuan Chang

и другие.

Journal of Thoracic Oncology, Год журнала: 2023, Номер 18(11), С. 1492 - 1503

Опубликована: Июль 5, 2023

BACKGROUND The role of family history lung cancer (LCFH) in screening using low-dose computed tomography (LDCT) has not been prospectively investigated and with long-term follow-up. METHODS A multicenter prospective study up to three rounds annual LDCT was conducted determine the detection rate LC asymptomatic first or second-degree relatives LCFH. RESULTS From 2007 2011, there were 1,102 participants enrolled, including 805 297 from simplex (SF) multiplex families (MF), respectively (54.2% female, 70.0% never-smokers). Last follow-up date May 05, 2021. overall 4.5% (50/1102). MF 9.4% (19/202) 4.4% (4/91) never-smokers who smoked, respectively. corresponding rates for SF 3.7% (21/569) 2.7% (6/223), Of them, 68.0% 22.0% cases stage I IV diseases, diagnoses within a 3-year interval initial younger, higher rate, more disease; thereafter, III/IV disease 66.7% (16/24) negative semi-positive nodules CT scans. Within 6-year interval, only maternal (modified ratio [RR]=4.46, 95% confidence [CI]=2.32–8.56) relative RR=5.41, CI=2.84–10.30) increased risk LC. CONCLUSION LCFH is factor LC, history, never-smokers, younger adults, those Randomized controlled trials are needed confirm mortality benefit

Язык: Английский

Процитировано

13
Why has there been such a long delay in the implementation of population lung cancer screening in the USA? DOI Creative Commons
Frederic W. Grannis

Academia Medicine, Год журнала: 2025, Номер 2(1)

Опубликована: Март 21, 2025

When three National Cancer Institute (NCI)–sponsored research trials demonstrated a striking improvement in survival with chest radiographic screening (CRS) the 1980s, critics questioned whether results were tainted by biases, including overdiagnosis, and posited long list of hypothetical risks, suggesting that lung cancer (LCS) would provide little benefit but might cause enormous harm. For more than 40 years, relatively small cadre individuals, often acting concert, relentlessly opposed implementation population CRS later computerized tomographic (CT LCS). Delays due to completion multiple randomized controlled trials; restriction CT LCS only those at highest risk; hyperbolic fear radiation carcinogenesis low doses; imposition shared decision-making (SDM), decision aids (DAs) incorporating misinformation; COVID-19 epidemic; an overly optimistic focus on molecular may have contributed delay. In 2024, we accumulated large body evidence demonstrating can prevent (LC) deaths through early-stage detection, permitting effective safe treatment. Yet, years after initial reports higher screening, number high-risk individuals screened remains USA. An opportunity save countless lives has been lost.

Язык: Английский

Процитировано

0